Moderna and AbCellera develop mRNA-encoded antibody therapy together
- Scientists are trying to get mosquitoes to deliver vaccines to humans
- Why are children born with “test tube babies” more prone to cancer?
- Japan purchased 120 million doses of AZ vaccine with only about 200K doses
- First fungal biome atlas reveals link to cancer
- Genetic signature that explains racial differences in prostate cancer severity
- High blood pressure may accelerate bone aging
Moderna and AbCellera develop mRNA-encoded antibody therapy together
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- Is the new COVID Omicron variant BA.4.6 more contagious?
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
Moderna and AbCellera develop mRNA-encoded antibody therapy together
Before the COVID-19 vaccine, Moderna’s company’s early vision was “committed to promoting the body’s own production of healing proteins.” Recently, pipelines such as infectious diseases and tumor vaccines have quickly been put on the company’s agenda. The original plan is still continuing, and is now being promoted through cooperation with the industry’s preferred antibody platform AbCellera.
Moderna will work with AbCellera to identify mRNA therapeutic antibodies against up to six targets. At the same time, Moderna will have the right to develop the antibody molecule to create mRNA encoding the antibody and use it to induce the production of healing proteins in the patient’s body.
“The development of effective mRNA-encoded antibody therapy requires two things, one is to build highly efficient antibodies suitable for high expression from RNA, and the other is to bring these RNA technologies to the clinic,” said Dr. Carl Hansen, CEO and co-founder of AbCellera. As the world’s leading artificial intelligence-driven antibody discovery technology platform, AbCellera aims to provide fast, diverse and flexible high-efficiency antibodies for a wide range of drug targets.”
Moderna became the first company to test monoclonal antibodies encoded by mRNA in clinical trials in early 2019. However, Moderna has not yet followed up with the use of mRNA-encoded antibodies for Phase II clinical trials. Moderna has disclosed the development of similar drug candidates that use nucleic acids to trigger the production of cytokines and hormones, showing that the number of antibodies and the rapid growth rate make it a major opportunity.
Both parties are interested in using mRNA to trigger the production of antibodies in the body, rather than generating them in a bioreactor, making manufacturing simplified, extending shelf life and enhancing the potential for tissue penetration. And AbCelera now hopes to cooperate with Moderna to achieve the final commercialization.
Previously, concerns about the safety of repeated administration of lipid nanoparticles for mRNA delivery cast a shadow over the early days of this method. Moderna provided the subjects with two doses of its lead antibody plan within a week, and no serious adverse events occurred, indicating that the antibody platform is suitable for repeated dosing (safety).
At the same time, the research and development results from AbCelera will be added to Moderna’s chikungunya virus (chikungunya virus, causing chikungunya fever) mRNA-encoded antibody therapy. Moderna conducted in vivo testing against the chikungunya virus in 2019. It contains two mRNA drug candidates that encode the heavy and light chains of antibodies against the virus. Moderna found a dose-dependent increase in antibody levels in its early trials.
(source:internet, reference only)
Disclaimer of medicaltrend.org
